Interview with Harvard Medical School's Dr. Toker & Harvard Medical School's and Science and Technology Park at Johns Hopkins's Dr. Mancini

Name: Interview with Harvard Medical School's Dr. Toker & Harvard Medical School's and Science and Technology Park at Johns Hopkins's Dr. Mancini
Uploaded: 2016-04-07
Duration: 7 min 39 s
Description: Interview regarding their article published in Oncotarget Volume 7, Issue 14 titled Oncogenic AKT1E17K mutation induces mammary hyperplasia but prevents HER2driven tumorigenesis

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access, biweekly journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing OncoTarget.

From January 1, 2021 Oncotarget is a biweekly journal that is published on Tuesday.

Request Conference Sponsorship

Oncotarget Videos with Outstanding Authors

Harvard Medical School's Dr. Toker & Harvard Medical School's and Science and Technology Park at Johns Hopkins's Dr. Mancini talk about their Publication in the Open-access Bio-medical Journal Oncotarget

Correspondence to - Alex Toker, email: atoker@bidmc.harvard.edu

Keywords: Akt, breast cancer, PI 3-kinase, HER2, estrogen receptor

Subscribe to TOC Alerts

Oncotarget Videos with Outstanding Authors

Harvard Medical School's Dr. Toker & Harvard Medical School's and Science and Technology Park at Johns Hopkins's Dr. Mancini talk about their Publication in the Open-access Bio-medical Journal Oncotarget